Contents

Sincalide

Chemical compound

This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this articlebyintroducing citations to additional sources. Find sources: "Sincalide" – news · newspapers · books · scholar · JSTOR (October 2014)

Sincalide

Clinical data
Other names	1-De(5-oxo-L-proline)-2-de-L-glutamine- 5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl) amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4- methylsulfanyl-butanoyl]amino]acetyl]amino]-3- (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl- butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl) carbamoyl]propanoic acid
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	Intravenous
ATC code	V04CC03 (WHO)
Legal status
Legal status	UK: Available on a named-patient basis US: ℞-only
Identifiers
IUPAC name α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
CAS Number	25126-32-3 Y
PubChem CID	32800
IUPHAR/BPS	864
ChemSpider	8009168 N
UNII	M03GIQ7Z6P
KEGG	D05845 Y
ChEMBL	ChEMBL1121 N
CompTox Dashboard (EPA)	DTXSID7048617
ECHA InfoCard	100.042.384
Chemical and physical data
Formula	C49H62N10O16S3
Molar mass	1143.27 g·mol−1
3D model (JSmol)	Interactive image
SMILES CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
InChI InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 N Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N N
NY (what is this?)  (verify)

Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.

Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

Clinical Use[edit]

Indications[edit]

Sincalide may be used to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystographyorultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals.^[1] It can also be used to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. In some instances it is used to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.^[2]

References[edit]

External links[edit]

• "KINEVAC (sincalide)]". DailyMed. U.S. National Library of Medicine.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.